Speculation Mounts About Price Tag for Emerging CAR Therapies – OncLive
OncLive |
Speculation Mounts About Price Tag for Emerging CAR Therapies
OncLive Chimeric antigen receptor (CAR) T-cell therapies could spawn a new and lucrative industry in anticancer immunotherapy, resulting in single-infusion treatments costing hundreds of thousands of dollars, and even attracting medical tourism from abroad … |
